Ascentage Pharma Group (AAPG) Forward P/S Multiple
The forward P/S multiple for Ascentage Pharma Group (AAPG) reflects the impact of geopolitical tensions between Beijing and Washington on share prices, with the current value standing at 8.50. Environmental responsibility regarding chemical disposal is coupled with serious challenges: prolonged waiting periods for regulatory verdicts and significant costs associated with the final stages of clinical drug trials.
Analytical breakdowns for Ascentage Pharma Corp (AAPG)
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Ascentage Pharma Group|AAPG - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Ascentage Pharma Group|AAPG - Company Aggregate Debts|Debts to Book Capitalization Ascentage Pharma Corp|AAPG - Long-Term Indebtedness|Company Short-Term Debts Ascentage Pharma|Quick Liquidity Indicator ascentage.com
- financial results and valuation multiples details:
AAPG - Final Profit|Expected Profit Ascentage Pharma Group|AAPG - Market Cap to Net Income|Forward P/E Multiple Ascentage|AAPG - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Ascentage Pharma Corp|AAPG - Operating profit EBITDA|Earnings per share for the last twelve months Ascentage Pharma|AAPG - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months ascentage.com|AAPG - Net earnings per share growth this year|Earnings growth forecast for next year Ascentage Pharma Group
- revenue and sales details:
Fundamental company analysis:Ascentage Pharma AAPG
High uncertainty regarding the clinical trial outcomes of Ascentage Pharma Group (AAPG) anti-tumor drugs directly impacts market expectations for future sales. By analyzing the forward price-to-sales valuation trend, an investor can observe the ratio of current market capitalization to projected revenue, which determines the extent to which the cost of capital is inflated relative to the risks of commercial failure within the competitive oncology segment.
Main competitors
Price-to-Projected Revenue Ratio BeiGene ONC|Market Cap to Expected Sales Ratio Halozyme Therapeutics, Inc. (HALO)|RevMed - Forward P/S Multiple|CG Oncology Therapeutics (CGON) - Forward Price-to-Revenue Multiple|URGN: Forward P/S Multiple|Market Cap to Future Revenue Ratio bicara.com (BCAX)|Price-to-Projected Revenue Ratio Personalis|Market Cap to Projected Revenue ERAS (Erasca Inc)|Forward Price-to-Revenue Multiple DCTH (Delcath)|Price to Expected Revenue Ratio YMAB|Forward P/S Multiple AURA (Aura Biosciences, Inc.)|Forward P/S Multiple Candel Therapeutics Inc. CADL|Accuray - Forward P/S Multiple|Projected Price to Revenue SELLAS Life Sciences (SLS)|ACTU: Forward P/S Multiple|Market Cap to Future Revenue Ratio Citius Oncology Inc (CTOR)|Forward Price-to-Revenue Multiple HURA|TARA: Forward Price to Sales|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|WHWK: Future Price to Revenue|Forward P/S Multiple TCRX (TScan Therapeutics, Inc.)|Forward Price to Sales CSBR|XBiotech USA - Forward P/S Multiple|CVM - Forward P/S Multiple|OS Therapies (OSTX) - Price-to-Projected Revenue Ratio|radiopharmtheranostics.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Artiva Biotherapeutics Inc.|Forward Price-to-Revenue Multiple Adlai Nortye Limited (ANL)|Forward P/S Multiple VERU|Forward P/S Multiple tempesttx.com (TPST)|Xilio Therapeutics - Forward Price-to-Revenue Multiple|Forward Price to Sales RENB|Mural Bio - Forward P/S Multiple|Projected Price to Revenue Kairos Pharma Ltd (KAPA)|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|CytoMed Therapeutics Limited - Forward Price to Sales|Price-to-Projected Revenue Ratio Curis Inc.|Market Cap to Future Revenue Ratio Apollomics Corp APLM|Forward Price-to-Revenue Multiple THAR (Tharimmune Corp)|Forward P/S Multiple advanbiomed.com (ADVB)|Price-to-Projected Revenue Ratio Genprex, Inc. GNPX|CLDI (Calidi Biotherapeutics Inc.) - Future Price to Revenue|Sunshine Biopharma, Inc. - Forward P/S Multiple|XBIO - Forward P/S Multiple|SLRX: Forward P/S Multiple|Kitov Pharma (PPBT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio American Oncology Network Inc|beigene.com - Future Price to Revenue|Forward P/S Multiple CKPT|elevationoncology.com (ELEV) - Projected Price to Revenue|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|Notable Labs, Ltd. - Forward P/S Multiple|VIRX - Forward P/S Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue NAYA|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
